Mineralocorticoid receptor activation and cardiac fibrosis

Clinical Science

Volumn 112, Issue 9-10, 2007, Pages 467-475

  Young, Morag J ^a   Lam, Emily Y M ^a   Rickard, Amanda J ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

11 hydroxysteroid dehydrogenase; Aldosterone; Cardiac fibrosis; Mineralocorticoid receptor; Oxidative stress; Vascular inflammation

Indexed keywords

ALDOSTERONE; CANRENOATE POTASSIUM; GLUCOCORTICOID; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; DRESSLER SYNDROME; HEART FAILURE; HEART MUSCLE FIBROSIS; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; BIOLOGICAL MODEL; CELL COMMUNICATION; FIBROSIS; HEART DISEASE; METABOLISM; VASCULITIS;

CELL COMMUNICATION; FIBROSIS; HEART DISEASES; HUMANS; MODELS, BIOLOGICAL; OXIDATIVE STRESS; RECEPTORS, MINERALOCORTICOID; VASCULITIS;

EID: 34248575767     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20060275     Document Type: Review

References (83)

1. Pitt, B., Zannad, F., Remme, W. J. et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709-717
2. Pitt, B., Remme, W., Zannad, F. et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309-1321
3. Juurlink, D. N., Mamdani, M. M., Lee, D. S. et al. (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 351, 543-551
4. Arriza, J. L., Weinberger, C., Cerelli, G. et al. (1987) Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237, 268-275
5. + metabolism. Kidney Int. 57, 1295-1298
6. Wang, Y., Zhang, J. and Geller, D. (2006) Renal distal tubule-specific mineralocorticoid receptor knockout mice: the role of renal and perhaps extrarenal MR in sodium homeostasis. Proceedings of the 32nd Annual Meeting of the International Aldosterone Conference, Boston, MA, U.S.A., pp. 16-17
7. Ronzaud, C., Berger, S., Loffing, J., Gretz, N. and Schutz, G. (2006) Renal principal cell-specific inactivation of the mineralocorticoid receptor. Proceedings of the 32nd Annual Meeting of the International Aldosterone Conference, Boston, MA, U.S.A., p. 26
8. Funder, J. W., Pearce, P. T., Smith, R. and Smith, A. I. (1988) Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242, 583-585
9. Funder, J. (2006) Aldosterone and the cardiovascular system: genomic and nongenomic effects. Endocrinology 147, 5564-5567
10. Stewart, P. M., Corrie, J. E., Shackleton, C. H. and Edwards, C. R. (1988) Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. J. Clin. Invest. 82, 340-349
11. Edwards, C. R., Burt, D. and Stewart, P. M. (1989) The specificity of the human mineralocorticoid receptor: clinical clues to a biological conundrum. J. Steroid Biochem. 32, 213-216
12. Pearce, P. and Funder, J. W. (1987) High affinity aldosterone binding sites (type I receptors) in rat heart. Clin. Exp. Pharmacol. Physiol. 14, 859-866
13. Funder, J. W., Pearce, P. T., Smith, R. and Campbell, J. (1989) Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors. Endocrinology 125, 2224-2226
14. Hadoke, P. W., Christy, C., Kotelevtsev, Y. V. et al. (2001) Endothelial cell dysfunction in mice after transgenic knockout of type 2, but not type 1, 11β-hydroxysteroid dehydrogenase. Circulation 104, 2832-2837
15. Christy, C., Hadoke, P. W., Paterson, J. M., Mullins, J. J., Seckl, J. R. and Walker, B. R. (2003) 11β-Hydroxysteroid dehydrogenase type 2 in mouse aorta: localization and influence on response to glucocorticoids. Hypertension 42, 580-587
16. Roland, B. L., Krozowski, Z. S. and Funder, J. W. (1995) Glucocorticoid receptor, mineralocorticoid receptors, 11 β-hydroxysteroid dehydrogenase-1 and -2 expression in rat brain and kidney: in situ studies. Mol. Cell. Endocrinol. 111, R1-R7
17. Roland, B. L., Li, K. X. and Funder, J. W. (1995) Hybridization histochemical localization of 11 β-hydroxysteroid dehydrogenase type 2 in rat brain. Endocrinology 136, 4697-4700
18. Lombes, M., Kenouch, S., Souque, A., Farman, N. and Rafestin-Oblin, M. E. (1994) The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11β-hydroxysteroid dehydrogenase. Endocrinology 135, 834-840
19. Roland, B. L. and Funder, J. W. (1996) Localization of 11β-hydroxysteroid dehydrogenase type 2 in rat tissues: in situ studies. Endocrinology 137, 1123-1128
20. Young, M., Head, G. and Funder, J. (1995) Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am. J. Physiol. 269, E657-E662
21. Alzamora, R., Michea, L. and Marusic, E. T. (2000) Role of 11β-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension 35, 1099-1104
22. Gomez Sanchez, E. P. (1991) What is the role of the central nervous system in mineralocorticoid hypertension? Am. J. Hypertens. 4, 374-381
23. Mihailidou, A. S. and Funder, J. W. (2005) Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids 70, 347-351
24. Mihailidou, A. S., Mardini, M., Fraser, T., Knights, D. and Funder, J. W. (2004) Agonist/antagonist activity of Cortisol in cardiomyocyte mineralocorticoid receptors is determined by redox state. Proceedings of the 30th Annual Meeting of the International Aldosterone Conference, New Orleans, LA, U.S.A., pp. 18-19
25. Wehling, M., Kasmayr, J. and Theisen, K. (1989) Fast effects of aldosterone on electrolytes in human lymphocytes are mediated by the sodium-proton-exchanger of the cell membrane. Bioch. Biophys. Res. Commun. 164, 961-967
26. Wehling, M., Kasmayr, J., Christ, M., Sippell, W., Theisen, K. and Muller, O. A. (1992) The early mineralocorticoid effector mechanism, the sodium-proton exchanger, is sensitized in lymphocytes from patients with Cushing's syndrome. Clin. Endocrinol. 37, 260-265
27. + pump. Circ. Res. 86, 37-42
28. Mihailidou, A. S., Mardini, M. and Funder, J. W. (2004) Rapid, nongenomic effects of aldosterone in the heart mediated by epsilon protein kinase C. Endocrinology 145, 773-780
29. Selye, H. (1946) The general adaptation syndrome and the diseases of adaptation. J. Clin. Endocrinol. 6, 117-230
30. Selye, H. (1950) Production of hypertension and hyalinosis by desoxycorticosterone. Br. Med. J. 1, 203-218
31. Simpson, S. A., Tait, J. F., Wettstein, A., Neher, R., von Euw, J. and Reichstein, T. (1953) Isolierung eines neuen kristallisierten Hormons aus Nebennerien mit besonders hoher Wirksamkeit auf den Mineralsoffwechsel. Experientia 9, 333-335
32. Brilla, C. G. and Weber, K. T. (1992) Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J. Lab. Clin. Med. 120, 893-901
33. Weber, K. T., Sun, Y., Tyagi, S. C. and Cleutjens, J. P. (1994) Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J. Mol. Cell. Cardiol. 26, 279-292
34. Brilla, C. G., Zhou, G., Matsubara, L. and Weber, K. T. (1994) Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J. Mol. Cell. Cardiol. 26, 809-820
35. Fullerton, M. J. and Funder, J. W. (1994) Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc. Res. 28, 1863-1867
36. Chun, T. Y. and Pratt, J. H. (2005) Aldosterone increases plasminogen activator inhibitor-1 synthesis in rat cardiomyocytes. Mol. Cell. Endocrinol. 239, 55-61
37. Chun, T. Y. and Pratt, J. H. (2004) Non-genomic effects of aldosterone: new actions and questions. Trends Endocrinol. Metab. 15, 353-354
38. Nagai, Y., Miyata, K., Sun, G. P. et al. (2005) Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 46, 1039-1045
39. Robert, V., Heymes, C., Silvestre, J. S., Sabri, A., Swynghedauw, B. and Delcayre, C. (1999) Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 33, 981-986
40. Nakano, S., Kobayashi, N., Yoshida, K., Ohno, T. and Matsuoka, H. (2005) Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats. Hypertension Res. 28, 925-936
41. Chander, P. N., Rocha, R., Ranaudo, J., Singh, G., Zuckerman, A. and Stier, Jr, C. T. (2003) Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP. J. Am. Soc. Nephrol. 14, 1990-1997
42. Guarda, E., Myers, P. R., Brilla, C. G., Tyagi, S. C. and Weber, K. T. (1993) Endothelial cell induced modulation of cardiac fibroblast collagen metabolism. Cardiovasc. Res. 27, 1004-1008
43. A receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 37, 1444-1449
44. Pu, Q., Neves, M. F., Virdis, A., Touyz, R. M. and Schiffrin, E. L. (2003) Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 42, 49-55
45. Lariviere, R., Day, R. and Schiffrin, E. L. (1993) Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 21, 916-920
46. B endothelin receptor antagonist bosentan. Can. J. Physiol. Pharmacol. 73, 390-398
47. Krug, A. W., Grossmann, C., Schuster, C. et al. (2003) Aldosterone stimulates epidermal growth factor receptor expression. J. Biol. Chem. 278, 43060-43066
48. Northcott, C., Florian, J. A., Dorrance, A. and Watts, S. W. (2001) Arterial epidermal growth factor receptor expression in deoxycorticosterone acetate-salt hypertension. Hypertension 38, 1337-1341
49. Florian, J. A., Dorrance, A., Webb, R. C. and Watts, S. W. (2001) Mineralocorticoids upregulate arterial contraction to epidermal growth factor. Am. J. Physiol. Regulatory Integrative Comp. Physiol. 281, R878-R886
50. Virdis, A., Neves, M. F., Amiri, F., Viel, E., Touyz, R. M. and Schiffrin, E. L. (2002) Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40, 504-510
51. Grossmann, C., Krug, A. W., Freudinger, R., Mildenberger, S., Voelker, K. and Gekle, M. (2006) Direct interaction between the human mineralocorticoid receptor and the human epidermal growth factor receptor promoter in cardiovascular cells. Proceedings of the 32nd Annual Meeting of the International Aldosterone Conference, Boston, MA, U.S.A., p. 14
52. Keaney, Jr, J. F., Guo, Y., Cunningham, D., Shwaery, G. T., Xu, A. and Vita, J. A. (1996) Vascular incorporation of α-tocopherol prevents endothelial dysfunction due to oxidized LDL by inhibiting protein kinase C stimulation. J. Clin. Invest. 98, 386-394
53. Kobayashi, N., Nakano, S., Mita, S. et al. (2002) Involvement of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats. J. Pharmacol. Exp. Ther. 301, 459-466
54. Rickard, A. J., Funder, J. W., Fuller, P. J. and Young, M. J. (2006) The role of the glucocorticoid receptor in mineralocorticoid/salt mediated cardiac fibrosis. Endocrinology. 147, 5901-5906
55. Wilson, P., Funder, J. and Young, M. (2004) Role of reactive oxygen species and NADPH oxidase in the generation of mineralocorticoid/salt cardiac fibrosis. Proceedings of the International Congress of Endocrinology, Lisbon, Portugal, OR97
56. Sun, Y., Zhang, J., Lu, L., Chen, S. S., Quinn, M. T. and Weber, K. T. (2002) Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am. J. Pathol. 161, 1773-1781
57. Lingen, M. W. (2001) Role of leukocytes and endothelial cells in the development of angiogenesis in inflammation and wound healing. Arch. Pathol. Lab. Med. 125, 67-71
58. Sun, Y. and Weber, K. T. (1998) Cardiac remodelling by fibrous tissue: role of local factors and circulating hormones. Ann. Med. 30, 3-8
59. Rocha, R., Rudolph, A. E., Frierdich, G. E. et al. (2002) Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 283, H1802-H1810
60. Young, M. J., Moussa, L., Dilley, R. and Funder, J. W. (2003) Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11β-hydroxysteroid dehydrogenase inactivation. Endocrinology 144, 1121-1125
61. Young, M. and Funder, J. (2003) Mineralocorticoid action and sodium-hydrogen exchange: studies in experimental cardiac fibrosis. Endocrinology 144, 3848-3851
62. Matsui, Y., Jia, N., Okamoto, H. et al. (2004) Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 43, 1195-1201
63. Collins, A. R., Schnee, J., Wang, W. et al. (2004) Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart. J. Am. Coll. Cardiol. 43, 1698-1705
64. Sam, F., Xie, Z., Ooi, H. et al. (2004) Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. Am. J. Hypertens. 17, 188-193
65. Weisberg, A. D., Albornoz, F., Griffin, J. P. et al. (2005) Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler. Thromb. Vasc. Biol. 25, 365-371
66. G-nitro-L-arginine methyl ester-induced myocardial injury. Circulation 108, 2517-2523
67. Luttun, A., Lupu, F., Storkebaum, E. et al. (2002) Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 22, 499-505
68. Young, M. J. and Funder, J. W. (2004) Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology 145, 3153-3157
69. Callera, G. E., Tostes, R. C., Yogi, A., Montezano, A. C. and Touyz, R. M. (2006) Endothelin-1-induced oxidative stress in DOCA-salt hypertension involves NADPH-oxidase-independent mechanisms. Clin. Sci. 110, 243-253
70. Callera, G. E., Touyz, R. M., Teixeira, S. A. et al. (2003) ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension 42, 811-817
71. Touyz, R. M., Mercure, C., He, Y. et al. (2005) Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase. Hypertension 45, 530-537
72. Zhao, W., Ahokas, R. A., Weber, K. T. and Sun, Y. (2006) ANG II-induced cardiac molecular and cellular events: role of aldosterone. Am. J. Physiol. Heart Circ. Physiol. 291, H336-H343
73. Sanz-Rosa, D., Cediel, E., de las Heras, N. et al. (2005) Participation of aldosterone in the vascular inflammatory response of spontaneously hypertensive rats: role of the NFκB/IκB system. J. Hypertens. 23, 1167-1172
74. Sanz-Rosa, D., Oubina, M. P., Cediel, E. et al. (2005) Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences. Antioxid. Redox Signaling 7, 1294-1301
75. Ward, M. R., Kanellakis, P., Ramsey, D., Funder, J. and Bobik, A. (2001) Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 104, 467-472
76. Funder, J. W. (2006) Mineralocorticoid receptors and cardiovascular damage: it's not just aldosterone. Hypertension 47, 634-635
77. Funder, J. W. (2004) Aldosterone, mineralocorticoid receptors and vascular inflammation. Mol. Cell. Endocrinol. 217, 263-269
78. Schmidt, B. M., Oehmer, S., Delles, C. et al. (2003) Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension 42, 156-160
79. + exchanger. Eur. J. Med. Chem. 38, 547-554
80. Mihailidou, A. S., Mardini, M. and Funder, J. W. (2003) Rapid non-genomic effects of aldosterone in the heart mediated by εPKC. Endocrinology 143, 773-780
81. Rogerson, F. M. and Fuller, P. J. (2003) Interdomain interactions in the mineralocorticoid receptor. Mol. Cell. Endocrinol. 200, 45-55
82. Li, Y., Suino, K., Daugherty, J. and Xu, H. E. (2005) Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor. Mol. Cell. 19, 367-380
83. Hultman, M. L., Krasnoperova, N. V., Li, S. et al. (2005) The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms. Mol. Endocrinol. 19, 1460-1473